135 related articles for article (PubMed ID: 26447565)
1. Synthesis, luminescence, and anti-tumor properties of MgSiO3:Eu-DOX-DPP-RGD hollow microspheres.
Lv R; Zhong C; Gulzar A; Gai S; He F; Gu R; Zhang S; Yang G; Yang P
Dalton Trans; 2015 Nov; 44(42):18585-95. PubMed ID: 26447565
[TBL] [Abstract][Full Text] [Related]
2. YVO4:Eu3+ functionalized porous silica submicrospheres as delivery carriers of doxorubicin.
Cheng Z; Ma P; Hou Z; Wang W; Dai Y; Zhai X; Lin J
Dalton Trans; 2012 Feb; 41(5):1481-9. PubMed ID: 22124278
[TBL] [Abstract][Full Text] [Related]
3. SiO2@YBO3:Eu3+ hollow mesoporous spheres for drug delivery vehicle.
Yang G; Gai S; Qu F; Yang P
ACS Appl Mater Interfaces; 2013 Jun; 5(12):5788-96. PubMed ID: 23705794
[TBL] [Abstract][Full Text] [Related]
4. Uniform magnesium silicate hollow spheres as high drug-loading nanocarriers for cancer therapy with low systemic toxicity.
Wang B; Meng W; Bi M; Ni Y; Cai Q; Wang J
Dalton Trans; 2013 Jun; 42(24):8918-25. PubMed ID: 23660815
[TBL] [Abstract][Full Text] [Related]
5. Up-conversion nanoparticle assembled mesoporous silica composites: synthesis, plasmon-enhanced luminescence, and near-infrared light triggered drug release.
Niu N; He F; Ma P; Gai S; Yang G; Qu F; Wang Y; Xu J; Yang P
ACS Appl Mater Interfaces; 2014 Mar; 6(5):3250-62. PubMed ID: 24521281
[TBL] [Abstract][Full Text] [Related]
6. A luminescent and mesoporous core-shell structured Gd2O3 : Eu(3+)@nSiO2@mSiO2 nanocomposite as a drug carrier.
Xu Z; Gao Y; Huang S; Ma Pa; Lin J; Fang J
Dalton Trans; 2011 May; 40(18):4846-54. PubMed ID: 21431226
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery and pH-responsive release of doxorubicin to cancer cells using calcium carbonate/hyaluronate/glutamate mesoporous hollow spheres.
Guo Y; Li H; Shi W; Zhang J; Feng J; Yang X; Wang K; Zhang H; Yang L
J Colloid Interface Sci; 2017 Sep; 502():59-66. PubMed ID: 28477470
[TBL] [Abstract][Full Text] [Related]
8. Luminescent GdVO4:Eu3+ functionalized mesoporous silica nanoparticles for magnetic resonance imaging and drug delivery.
Huang S; Cheng Z; Ma P; Kang X; Dai Y; Lin J
Dalton Trans; 2013 May; 42(18):6523-30. PubMed ID: 23474744
[TBL] [Abstract][Full Text] [Related]
9. A multifunctional biphasic suspension of mesoporous silica encapsulated with YVO4:Eu3+ and Fe3O4 nanoparticles: synergistic effect towards cancer therapy and imaging.
Shanta Singh N; Kulkarni H; Pradhan L; Bahadur D
Nanotechnology; 2013 Feb; 24(6):065101. PubMed ID: 23324398
[TBL] [Abstract][Full Text] [Related]
10. Fabrication of hollow and porous structured GdVO4:Dy3+ nanospheres as anticancer drug carrier and MRI contrast agent.
Kang X; Yang D; Ma P; Dai Y; Shang M; Geng D; Cheng Z; Lin J
Langmuir; 2013 Jan; 29(4):1286-94. PubMed ID: 23281806
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells.
Li J; Liu F; Shao Q; Min Y; Costa M; Yeow EK; Xing B
Adv Healthc Mater; 2014 Aug; 3(8):1230-9. PubMed ID: 24550203
[TBL] [Abstract][Full Text] [Related]
12. CPMV-induced synthesis of hollow mesoporous SiO2 nanocapsules with excellent performance in drug delivery.
Kumar K; Kumar Doddi S; Arunasree MK; Paik P
Dalton Trans; 2015 Mar; 44(9):4308-17. PubMed ID: 25640798
[TBL] [Abstract][Full Text] [Related]
13. Rattle-type Fe(3)O(4)@SiO(2) hollow mesoporous spheres as carriers for drug delivery.
Zhu Y; Ikoma T; Hanagata N; Kaskel S
Small; 2010 Feb; 6(3):471-8. PubMed ID: 19943250
[TBL] [Abstract][Full Text] [Related]
14. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
17. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
18. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of Europium-Doped Fluorapatite Nanorods and Their Biomedical Applications in Drug Delivery.
Zeng H; Li X; Sun M; Wu S; Chen H
Molecules; 2017 May; 22(5):. PubMed ID: 28481233
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional hollow CaF2:Yb(3+)/Er(3+)/Mn(2+)-poly(2-Aminoethyl methacrylate) microspheres for Pt(IV) pro-drug delivery and tri-modal imaging.
Deng X; Dai Y; Liu J; Zhou Y; Ma P; Cheng Z; Chen Y; Deng K; Li X; Hou Z; Li C; Lin J
Biomaterials; 2015 May; 50():154-63. PubMed ID: 25736505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
